57 results about "Haemophilus influenzae type" patented technology

The invention provides a multivalent immunogenic composition, which includes an inactivated hepatitis A antigen and an inactivated poliovirus. The composition also can further include over one or two of a purified pertussis antigen, diphtheria toxoid, tetanus toxoid, filamentous hemagglutinin, Haemophilus influenzae type b polysaccharide, Neisseria meningitidis capsular polysaccharide, a hepatitis B virus antigen, enterovirus 71 and a coxsackievirus A16 antigen, and a physiologically acceptable carrier. The composition involved in the invention is employed to immunize the inoculated population in the form of a bivalent vaccine or more combined vaccines. Without reducing the immune effects of each immunizing antigen, the inoculation number of times can be reduced at the same time, and the time and human resources can also be saved.

A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide of Haemophilus influenzae type b and tetanus toxoid or diphteria toxoid, which may be reconstituted from a lyophilized state by the other components of the vaccine. The administration of the multiple component vaccine results in no diminution in the immunogenicity of any component as a result of interference by other components of the vaccine.

The invention provides a diphtheria, tetanus and acellular pertussis / Haemophilus influenzae type b - group A and C meningococcus combined vaccine, which has the characteristics of high safety, high efficacy, high controllability and prevention of multiple diseases through one injection, satisfies relevant requirements on absorbed diphtheria, tetanus and acellular pertussis combined vaccines, Haemophilus influenzae type b combined vaccines and group A and C meningococcus combined vaccines in the Third Part of Chinese Pharmacopoeia (2010) and proposed Rules on Production and Inspection of Diphtheria, Tetanus and acellular Pertussis / Haemophilus influenzae Type b - Group A and C Meningococcus Combined Vaccines, and achieves an effect of putting into practical application.

The invention designs specific primers for streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex, and establishes a multiple landing PCR(Polymerase Chain Reaction) detection kit and a detection method for simultaneously detecting the bacteria, adopting agarose gel electrophoresis for detecting PCR products. The kit comprises a 10*PCR buffer solution, MgCl2, dNTP, TaqDNA polymerase, BSA(Bovine Serum Albumin), positive control DNAs of streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex, a streptococcus pneumoniae primer, a haemophilus influenzae type b primer and a mycobacterium tuberculosis complex primer. The kit can simultaneously quickly detect streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex in a lower respiratory tract sample. The multiple landing PCR detection kit and detection method established by the invention are quick, simple, specific and sensitive, and can be used for rapid diagnosis and epidemiological investigation of infection of streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex.

A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.

The invention discloses a method detecting content of Hib (haemophilus influenzae type b) polysaccharide antibodies in serum through adopting the ELISA method. The method provided by the invention mainly comprises the following steps: I, coating; II, applying sample; III, adding enzyme labeled antibodies; IV, substrate adding and coloration; V, reaction termination; and VI, color comparison. The method has the benefits that bovine serum albumin is adopted to substitute human serum albumin and serves as a sealing agent during the content detection of Hib polysaccharide antibodies in serum, so that the difficult problem that the sealing agent in an experiment needs a lot, yet the human serum albumin is short and high in price is solved, cost is greatly reduced, and the bovine serum albumin is easy to obtain, as a result, the popularization of the method can be facilitated; and the reaction time is changed into 16 hours at 2 to 8 DEG C, so that more serum can be detected at one time, the reaction time is sufficient, difference among plates is reduced, and the improvement on the detection accuracy is facilitated.

The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly / disassembly of the structure. The invention also relates to uses of these polynucleotides and / or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.

The invention discloses a preparation method of Haemophilus influenzae type B polysaccharide-conjugated vaccine. The preparation method is: extract the polysaccharide of Haemophilus influenzae type B, and dissolve PRP polysaccharide to 20 mg / ml with ultrapure water or water for injection at room temperature According to the condition that the mass ratio of PRP and CDAP is 1, CDAP is added and maintained for 1.5 min. Adjust the pH to 9.5 with 0.3M NaOH and maintain it for 3 minutes. Add solid ADH according to the condition that the mass ratio of ADH to PRP polysaccharide is 4:1. Adjust the pH to 9.5 with 0.3M NaOH and maintain it for 1h. 2-8°C, 0.2M NaCl dialysis; B. The dialyzed PRP-AH was mixed with 20mg / ml TT solution at a mass ratio of 1:2. Adjust the pH to 5.0 with 0.1M HCL, then add solid EDAC at a ratio of 10:1 mass ratio between EDAC and PRP, maintain the pH at room temperature at 5.060min, and adjust the pH to 7.5 with 0.3M NaOH for 30min.

A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.

The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

The invention discloses a high-density culture and production method of bacterium capsular polysaccharide with haemophilus influenzae type b. The method comprises following steps: subculturing Hib strains from a first generation to a fourth generation, carrying out culture in a seeding tank, carrying out fermentation and culture in a fermentation tank, killing bacteria, acquiring a supernatant, and purifying the supernatant. Beneficial effects of the invention are as follows: (1) by culturing Hib bacteria to a high concentration, output of Hib capsular polysaccharide is improved by 50% to 100% on the basis of the output of Hib capsular polysaccharide produced by the traditional way, and produced capsular polysaccharide meets the national standard; (2) by controlling nucleic acids, protein, and other impurities in a zymotic fluid to a low level, the number of times of phenol extracting for removing impurity protein is reduced for relatively low protein content, thereby reducing phenol amount used in subsequent purifying processes, reducing environmental pollution, and reducing production cost; and (3) output of polysaccharide is stable, and content of refined glycoprotein, endotoxin, and other impurities after the purifying is substantially lower than the national control standard.

The invention discloses a polymyxin B magnetic bead, a preparation method and an application thereof. 3 o 4 Nano-magnetic beads and polymyxin B solution are mixed and then stirred at 40-60°C for 2-5 hours to obtain Fe coated with polymyxin B on the surface 3 o 4 Nano magnetic beads, that is, polymyxin B magnetic beads. The polymyxin B magnetic beads include Fe 3 o 4 Nano magnetic beads and coated in Fe 3 o 4 Polymyxin B on the surface of magnetic nanobeads. The polymyxin B magnetic beads prepared by the present invention are combined with the free negatively charged phosphate groups of lipoproteins on the cell membrane of Haemophilus influenzae type b through the specific polycationic ring of the polymyxin B molecule through electrostatic interaction, and have high accuracy. High and specific characteristics. It can quickly enrich trace amounts of Haemophilus influenzae type b from cerebral effusion and achieve good adsorption effect. At the same time, the detection efficiency and sensitivity of Haemophilus influenzae type b are improved.

The invention discloses a preparation method of a non-adjuvant Haemophilus influenzae type b conjugate vaccine freeze-drying agent, which includes formulation, mixture preparation and freeze-drying process. In the process of vacuum freeze-sublimation drying in the freeze-drying process to remove free water, the present invention controls the temperature of the bottled material below the eutectic point of free water and bound water to eliminate the aggregation of CRM197 protein; removes free water by desorption and drying in vacuum During the process, the temperature of the bottled material is controlled below the degradation point to eliminate the degradation of the Hib capsule structure, so that the Haemophilus influenzae type b conjugate vaccine freeze-dried agent does not need to add an adjuvant technical solution, which overcomes the protein aggregation existing in the prior art , structural degradation, and the problems and shortcomings of adding adjuvants, the Haemophilus influenzae type b combined vaccine freeze-dried agent has achieved the purpose of eliminating protein aggregation and structural degradation without adding adjuvants.